COMMUNIQUÉS West-GlobeNewswire

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
26/08/2025
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma [...]
Syndax Announces Participation in September Investor Conferences
26/08/2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Voyager to Present at Upcoming Investor Conferences
26/08/2025
LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company [...]
EyePoint Announces Participation at Upcoming Investor Conferences
26/08/2025
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with [...]
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
26/08/2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a [...]
Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet
26/08/2025
Communiqué de presse Nicox annonce la mise en ligne d’une page « Questions-Réponses » sur son site internet 26 août 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, [...]
Nicox Announces Shareholder Q&A Webpage Available
26/08/2025
Press Release Nicox Announces Shareholder Q&A Webpage Available August 26, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology [...]
Ariceum Therapeutics Appoints David Schilansky as Chief Executive Officer and Announces New Leadership to Advance Next Phase of Development
26/08/2025
David Schilansky transitions to CEO, bringing 25 years of company-building, scaling and financing to advance Ariceum’s pipeline of novel radiotherapeutics Initiation of Phase 1/2 SANTANA-225 study of 225Ac-SSO110 in [...]
Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75%
26/08/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira
26/08/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION COPENHAGEN, Denmark, [...]
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire
26/08/2025
PannTheraPi se prépare pour mener son premier essai clinique de phase IIa avec le PTI5803 chez des patients atteints d'épilepsie résistante et accélérer le développement de son portefeuille propriétaire Dossier de pré- [...]
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline
26/08/2025
PannTheraPi prepares plans to conduct its first Phase IIa clinical trial with PTI5803 in patients with resistant epilepsy and accelerate the development of its proprietary pipeline Pre-submission file completed with [...]
PathAI Expands AISight® Dx Primary Diagnosis Clearance to Support VENTANA DP 200 and DP 600 Slide Scanners Through Predetermined Change Control Plan (PCCP)
26/08/2025
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced the expansion of the AISight® Dx digital pathology image management [...]
CancerVax Achieves Major Milestones and Files Foundational Patent Application
26/08/2025
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform Lehi, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, August 26, 2025 – CancerVax [...]
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
26/08/2025
ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio [...]
Synergy CHC Corp. Announces Pricing of $4.375 Million Public Offering
26/08/2025
WESTBROOK, Maine, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (Nasdaq: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced the pricing of an underwritten public [...]
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
25/08/2025
WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced an update on institutional ownership of the Company’s outstanding common stock, as [...]
Over 2,000 Successful Surgeries for Drug-Resistant Epilepsy
25/08/2025
KFSHRC Achieves a Breakthrough in Treating Epilepsy Through Stereo-EEG RIYADH, Saudi Arabia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has reinforced its Epilepsy [...]
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
25/08/2025
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today [...]

Pages